Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Connect Biopharma Holdings LtdCNTB · Entity 6516 | Director · Chief Executive Officer | March 16, 2026 | March 16, 2026 |
| HERON THERAPEUTICS, INC. /DE/HRTX · Entity 7133 | Director · Chief Executive Officer | January 18, 2023 | January 20, 2023 |
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | Director | August 19, 2026 | August 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Connect Biopharma Holdings Ltd
Report date March 16, 2026 · Filed March 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 95,147 |
Reported balance
Holding disclosure · report date 2026-03-16 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 95,147 |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Joint Account with Spouse | 128,887 |
Reported balance
Holding disclosure · report date 2026-03-16 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 128,887 |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.77 · Expires 2034-06-12 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-16 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F1: The stock option vests and becomes exercisable over four years, with 25% vesting on the first anniversary of the date of grant, and then with respect to the remaining shares on a ratable monthly basis over the next three years, subject to continuous service with the Company as of each applicable vesting date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.97 · Expires 2034-12-26 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-16 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F1: The stock option vests and becomes exercisable over four years, with 25% vesting on the first anniversary of the date of grant, and then with respect to the remaining shares on a ratable monthly basis over the next three years, subject to continuous service with the Company as of each applicable vesting date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.69 · Expires 2035-12-26 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-16 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F2: The stock option vests and becomes exercisable on a ratable monthly basis over four years, subject to continuous service with the Company as of each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable over four years, with 25% vesting on the first anniversary of the date of grant, and then with respect to the remaining shares on a ratable monthly basis over the next three years, subject to continuous service with the Company as of each applicable vesting date.
F2: The stock option vests and becomes exercisable on a ratable monthly basis over four years, subject to continuous service with the Company as of each applicable vesting date.
HERON THERAPEUTICS, INC. /DE/
Report date January 18, 2023 · Filed January 20, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.13 · Expires 2033-01-18 | Direct | 850,000 |
Reported balance
After 2023-01-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-18 · Grant · Acquired 850,000 · Balance 850,000 F1: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant.
Kiniksa Pharmaceuticals International, plc
Report date August 19, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary ShareSEC Table I · non-derivative | Direct | 12,745 |
Reported balance
After 2026-08-19 transaction · row 1
1 source rowRow 1 · 2026-08-19 · Gift · Disposed 2,600 · Balance 12,745 F1: This transaction involves a bona fide gift of securities from the reporting person to a donor advised fund. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction involves a bona fide gift of securities from the reporting person to a donor advised fund.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 19, 2026 Filed Aug 21, 2026 20:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GiftClass A Ordinary Share | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001384243-26-000014 · form4-08212026_080804.xml · nonDerivative · entry 1 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,745 F1 · kind: This transaction involves a bona fide gift of securities from the reporting person to a donor advised fund. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:52 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Units · Derivative | 2,799 | $0.00 | $0.00 |
DisclosureSEC source: 0001384243-26-000012 · form4-06022026_080623.xml · derivative · entry 4 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 2,799 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4 · derivative.exercise_date: The RSUs vested in a single installment on May 29, 2026; there was no expiration date for the RSUs. F4 · derivative.expiration_date: The RSUs vested in a single installment on May 29, 2026; there was no expiration date for the RSUs. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:52 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 2,026 | $0.00 | $0.00 |
DisclosureSEC source: 0001384243-26-000012 · form4-06022026_080623.xml · derivative · entry 3 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,026 Underlying: Class A Ordinary Shares · 2,026 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026. F3 · derivative.expiration_date: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:52 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 12,158 | $0.00 Strike: $48.38 | $0.00 |
DisclosureSEC source: 0001384243-26-000012 · form4-06022026_080623.xml · derivative · entry 2 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,185 Underlying: Class A Ordinary Shares · 12,158 shares Expires 2036-05-28 F2 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:52 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 2,799 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001384243-26-000012 · form4-06022026_080623.xml · nonDerivative · entry 1 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| April 28, 2026 Filed Apr 29, 2026 20:46 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 13,099 | $0.00 Strike: $14.33 | $0.00 |
DisclosureSEC source: 0001384243-26-000010 · form4-04292026_080403.xml · derivative · entry 3 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,237 Underlying: Class A Ordinary Shares · 13,099 shares Expires 2031-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 28, 2026 Filed Apr 29, 2026 20:46 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 13,099 | $50.10 | $656,259.90 |
DisclosureSEC source: 0001384243-26-000010 · form4-04292026_080403.xml · nonDerivative · entry 2 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,546 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $50.00 and $50.725. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| April 28, 2026 Filed Apr 29, 2026 20:46 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 13,099 | $14.33 | $187,708.67 |
DisclosureSEC source: 0001384243-26-000010 · form4-04292026_080403.xml · nonDerivative · entry 1 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,645 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 6,901 | $0.00 Strike: $14.33 | $0.00 |
DisclosureSEC source: 0001384243-26-000008 · form4-04082026_080443.xml · derivative · entry 3 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,336 Underlying: Class A Ordinary Shares · 6,901 shares Expires 2031-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 6,901 | $50.00 | $345,050.00 |
DisclosureSEC source: 0001384243-26-000008 · form4-04082026_080443.xml · nonDerivative · entry 2 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,546 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $50.00 and $50.015. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| April 06, 2026 Filed Apr 8, 2026 20:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 6,901 | $14.33 | $98,891.33 |
DisclosureSEC source: 0001384243-26-000008 · form4-04082026_080443.xml · nonDerivative · entry 1 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,447 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025. Read SEC document |
| February 12, 2026 Filed Feb 12, 2026 21:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 2,690 | $0.00 Strike: $15.47 | $0.00 |
DisclosureSEC source: 0001384243-26-000004 · form4-02122026_090237.xml · derivative · entry 6 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 2,690 shares Expires 2029-05-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 12, 2026 Filed Feb 12, 2026 21:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 2,690 | $45.00 | $121,050.00 |
DisclosureSEC source: 0001384243-26-000004 · form4-02122026_090237.xml · nonDerivative · entry 4 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,546 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025. Read SEC document |
| February 12, 2026 Filed Feb 12, 2026 21:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 2,690 | $15.47 | $41,614.30 |
DisclosureSEC source: 0001384243-26-000004 · form4-02122026_090237.xml · nonDerivative · entry 3 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,236 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 21:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 110 | $0.00 Strike: $15.47 | $0.00 |
DisclosureSEC source: 0001384243-26-000004 · form4-02122026_090237.xml · derivative · entry 5 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,690 Underlying: Class A Ordinary Shares · 110 shares Expires 2029-05-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 21:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 110 | $45.00 | $4,950.00 |
DisclosureSEC source: 0001384243-26-000004 · form4-02122026_090237.xml · nonDerivative · entry 2 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,546 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 21:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 110 | $15.47 | $1,701.70 |
DisclosureSEC source: 0001384243-26-000004 · form4-02122026_090237.xml · nonDerivative · entry 1 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025. Read SEC document |
| February 04, 2026 Filed Feb 4, 2026 23:24 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 2,602 | $0.00 Strike: $15.47 | $0.00 |
DisclosureSEC source: 0001384243-26-000002 · form4-02042026_110219.xml · derivative · entry 9 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,800 Underlying: Class A Ordinary Shares · 2,602 shares Expires 2029-05-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 04, 2026 Filed Feb 4, 2026 23:24 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 2,602 | $45.02 | $117,142.04 |
DisclosureSEC source: 0001384243-26-000002 · form4-02042026_110219.xml · nonDerivative · entry 6 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,546 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025. F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $45.00 and $45.05. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 04, 2026 Filed Feb 4, 2026 23:24 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 2,602 | $15.47 | $40,252.94 |
DisclosureSEC source: 0001384243-26-000002 · form4-02042026_110219.xml · nonDerivative · entry 5 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025. Read SEC document |
| February 03, 2026 Filed Feb 4, 2026 23:24 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 12,528 | $0.00 Strike: $15.47 | $0.00 |
DisclosureSEC source: 0001384243-26-000002 · form4-02042026_110219.xml · derivative · entry 8 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,402 Underlying: Class A Ordinary Shares · 12,528 shares Expires 2029-05-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 03, 2026 Filed Feb 4, 2026 23:24 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 12,528 | $45.27 | $567,142.56 |
DisclosureSEC source: 0001384243-26-000002 · form4-02042026_110219.xml · nonDerivative · entry 4 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,546 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $45.00 and $45.48. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 03, 2026 Filed Feb 4, 2026 23:24 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 12,528 | $15.47 | $193,808.16 |
DisclosureSEC source: 0001384243-26-000002 · form4-02042026_110219.xml · nonDerivative · entry 3 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 23:24 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 830 | $0.00 Strike: $15.47 | $0.00 |
DisclosureSEC source: 0001384243-26-000002 · form4-02042026_110219.xml · derivative · entry 7 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,930 Underlying: Class A Ordinary Shares · 830 shares Expires 2029-05-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 23:24 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 830 | $45.00 | $37,350.00 |
DisclosureSEC source: 0001384243-26-000002 · form4-02042026_110219.xml · nonDerivative · entry 2 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,546 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $45.00 and $45.02. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 23:24 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 830 | $15.47 | $12,840.10 |
DisclosureSEC source: 0001384243-26-000002 · form4-02042026_110219.xml · nonDerivative · entry 1 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,376 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 20,129 | $0.00 Strike: $10.36 | $0.00 |
DisclosureSEC source: 0001384243-25-000004 · form4-12172025_091228.xml · derivative · entry 3 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 20,129 shares Expires 2028-02-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 20,129 | $41.51 | $835,554.79 |
DisclosureSEC source: 0001384243-25-000004 · form4-12172025_091228.xml · nonDerivative · entry 2 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,546 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $41.19 and $41.78. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 20,129 | $10.36 | $208,536.44 |
DisclosureSEC source: 0001384243-25-000004 · form4-12172025_091228.xml · nonDerivative · entry 1 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025. Read SEC document |
| June 11, 2025 Filed Jun 11, 2025 21:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 12,336 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001415889-25-016724 · form4-06112025_090650.xml · derivative · entry 9 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 12,336 shares Expires 2027-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| June 11, 2025 Filed Jun 11, 2025 21:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 12,336 | $30.39 | $374,891.04 |
DisclosureSEC source: 0001415889-25-016724 · form4-06112025_090650.xml · nonDerivative · entry 6 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,546 F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $30.28 and $30.5801. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| June 11, 2025 Filed Jun 11, 2025 21:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 12,336 | $3.80 | $46,876.80 |
DisclosureSEC source: 0001415889-25-016724 · form4-06112025_090650.xml · nonDerivative · entry 5 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 21:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 8,212 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001415889-25-016724 · form4-06112025_090650.xml · derivative · entry 8 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,336 Underlying: Class A Ordinary Shares · 8,212 shares Expires 2027-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 21:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 8,212 | $30.36 | $249,316.32 |
DisclosureSEC source: 0001415889-25-016724 · form4-06112025_090650.xml · nonDerivative · entry 4 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,546 F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $30.00 and $30.52. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 21:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 8,212 | $3.80 | $31,205.60 |
DisclosureSEC source: 0001415889-25-016724 · form4-06112025_090650.xml · nonDerivative · entry 3 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 21:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 6,900 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001415889-25-016724 · form4-06112025_090650.xml · derivative · entry 7 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,548 Underlying: Class A Ordinary Share · 6,900 shares Expires 2027-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 21:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 6,900 | $30.26 | $208,794.00 |
DisclosureSEC source: 0001415889-25-016724 · form4-06112025_090650.xml · nonDerivative · entry 2 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,546 Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 21:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 6,900 | $3.80 | $26,220.00 |
DisclosureSEC source: 0001415889-25-016724 · form4-06112025_090650.xml · nonDerivative · entry 1 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,446 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2025 Filed Jun 5, 2025 20:53 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Units · Derivative | 3,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015784 · form4-06052025_080657.xml · derivative · entry 4 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 3,173 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4 · derivative.exercise_date: The RSUs vested in a single installment on June 5, 2025; there was no expiration date for the RSUs. F4 · derivative.expiration_date: The RSUs vested in a single installment on June 5, 2025; there was no expiration date for the RSUs. Read SEC document |
| June 05, 2025 Filed Jun 5, 2025 20:53 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 3,173 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-015784 · form4-06052025_080657.xml · nonDerivative · entry 1 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,546 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 20:53 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 2,799 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015784 · form4-06052025_080657.xml · derivative · entry 3 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,799 Underlying: Class A Ordinary Shares · 2,799 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025. F3 · derivative.expiration_date: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 20:53 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 16,798 | $0.00 Strike: $29.11 | $0.00 |
DisclosureSEC source: 0001415889-25-015784 · form4-06052025_080657.xml · derivative · entry 2 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,798 Underlying: Class A Ordinary Shares · 16,798 shares Expires 2035-06-02 F2 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Units · Derivative | 4,373 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015994 · form4-06072024_080604.xml · derivative · entry 4 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Shares · 4,373 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F4 · derivative.exercise_date: The RSUs vested in a single installment on June 6, 2024; there was no expiration date for the RSUs. F4 · derivative.expiration_date: The RSUs vested in a single installment on June 6, 2024; there was no expiration date for the RSUs. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 4,373 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-015994 · form4-06072024_080604.xml · nonDerivative · entry 1 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,373 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 3,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015994 · form4-06072024_080604.xml · derivative · entry 3 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,173 Underlying: Class A Common Shares · 3,173 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest in their entirety on the first anniversary date of the grant, June 5, 2024. F3 · derivative.expiration_date: The RSUs vest in their entirety on the first anniversary date of the grant, June 5, 2024. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 19,040 | $0.00 Strike: $19.71 | $0.00 |
DisclosureSEC source: 0001415889-24-015994 · form4-06072024_080604.xml · derivative · entry 2 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,040 Underlying: Class A Common Shares · 19,040 shares Expires 2034-06-04 F2 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant. The date of the grant is June 5, 2024. Read SEC document |
| June 29, 2023 Filed Jul 3, 2023 20:15 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-010559 · form4-07032023_040701.xml · derivative · entry 2 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Shares · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vested in a single installment on June 29, 2023; there was no expiration date for the RSUs. F2 · derivative.expiration_date: The RSUs vested in a single installment on June 29, 2023; there was no expiration date for the RSUs. Read SEC document |
| June 29, 2023 Filed Jul 3, 2023 20:15 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-010559 · form4-07032023_040701.xml · nonDerivative · entry 1 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 20:21 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 4,373 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-009426 · form4-06082023_080630.xml · derivative · entry 2 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,373 Underlying: Class A Common Shares · 4,373 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest in their entirety on the first anniversary of the date of the grant, June 6, 2023. F3 · derivative.expiration_date: The RSUs vest in their entirety on the first anniversary of the date of the grant, June 6, 2023. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 20:21 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 26,236 | $0.00 Strike: $15.19 | $0.00 |
DisclosureSEC source: 0001415889-23-009426 · form4-06082023_080630.xml · derivative · entry 1 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,236 Underlying: Class A Common Shares · 26,236 shares Expires 2033-06-05 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant. The date of the grant is June 6, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.